A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Given Daily for 21 Days Followed by 7 Days Off Schedule in Patients With Advanced GI Tumors.
Minnelide™, developed by Minneamrita Therapeutics LLC, is currently undergoing a Phase 1 clinical trial aimed at establishing the maximum tolerated dose (MTD) and assessing dose-limiting toxicities (DLT) in patients with advanced gastrointestinal tumors. The market for advanced GI tumors is significant, with a growing demand for innovative therapies due to the limitations of current treatment options. If successful, Minnelide™ could position itself as a novel therapeutic agent in a competitive landscape that includes established chemotherapeutics and emerging biologics. The completion of this trial could pave the way for Phase 2 studies, enhancing investor interest and potential partnerships for further development and commercialization.
Indication: Advanced Gastrointestinal Tumors
Modality: small molecule
Target: Heat Shock Protein 70 (HSP70) and apoptosis pathways via caspase activation.
Sponsor: Minneamrita Therapeutics LLC
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Heat Shock Protein 70 (HSP70) and apoptosis pathways via caspase activation.
View original source fields
Condition raw: Advanced Gastrointestinal Tumors
Condition normalized: Advanced Gastrointestinal Tumors
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Heat Shock Protein 70 (HSP70) and apoptosis pathways via caspase activation.
Target normalized: Heat Shock Protein 70 (HSP70) and apoptosis pathways via caspase activation.